Acepodia, Inc. (6976.TWO)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Shih-Chia Hsiao Ph.D. | Co-Founder, CEO, President & Chairman | -- | -- | -- |
| Dr. Yuhmin Yang Ph.D. | Co-Founder | -- | -- | 1948 |
| Leo OuYang | Senior Director of Accounting & Financial Officer | -- | -- | -- |
| YanDa Lai | Director of Operations | -- | -- | -- |
| Ms. Yajun Wang Ph.D. | Chief Technical Officer, Chief Quality Officer & VP of Quality | -- | -- | -- |
| Ms. Jessica Lee M.B.A., M.S. | Head of Business Development | -- | -- | -- |
| Stephanie Hsiao | Secretary | -- | -- | -- |
Acepodia, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
Description
Acepodia, Inc. operates as a clinical stage biotechnology company. The company engages in developing cell therapies with its antibody cell conjugation (ACC) platform technology to address cancer care. It links tumor targeting antibodies to its proprietary immune cells, such as gamma delta 2 T cells to create novel ACE therapies. In addition, the company develops ACE 1831 targeting CD20 that is in phase 1 clinical trial; ACE 2016 targeting EGFR, which is in preclinical study; ACE1708; and ACE1702 targeting HER2 that is in phase 1 clinical trial. Acepodia Inc. has strategic clinical collaboration with Pfizer Inc. for the development of antibody-cell conjugation-based cell therapies in autoimmune diseases. The company is based in Grand Cayman, the Cayman Islands.
Corporate Governance
Upcoming Events
Upcoming Events Information Not Available
Recent Events
Recent Events Information Not Available